Company logo

PLSE - Pulse Biosciences, Inc.

NASDAQ -> Healthcare -> Medical Instruments & Supplies
Hayward, United States
Type: Equity

PLSE price evolution
PLSE
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Jan 2023
Current assets
Cash $50.39 $58.75 $54.1 $61.14
Short term investments
Net receivables
Inventory
Total current assets $51.62 $59.96 $54.95 $62.15
Long term investments
Property, plant & equipment $9.11 $9.43 $9.73 $10.02
Goodwill & intangible assets $4.84 $5.01 $5.17 $5.34
Total noncurrent assets $14.32 $14.8 $15.27 $15.73
Total investments
Total assets $65.94 $74.76 $70.22 $77.88
Current liabilities
Accounts payable $1.41 $1.79 $2.16 $1.57
Deferred revenue $0
Short long term debt $1.02 $0.97 $1.74 $1.81
Total current liabilities $5.43 $5.61 $6.99 $5.98
Long term debt $8.37 $8.64 $73.9 $65
Total noncurrent liabilities $8.37 $8.64 $73.9 $74.14
Total debt $9.38 $9.62 $75.63 $75.96
Total liabilities $13.8 $14.26 $80.89 $80.13
Shareholders' equity
Retained earnings -$324.98 -$314.42 -$304.51 -$294.7
Other shareholder equity
Total shareholder equity $52.15 $60.5 -$10.67 -$2.25
(in millions $) 31 Jan 2023 31 Dec 2021 31 Dec 2020 31 Dec 2019
Current assets
Cash $61.14 $28.61 $12.46 $6.9
Short term investments $8.01 $18.5
Net receivables $0.06
Inventory $5.82
Total current assets $62.15 $36.63 $22.34 $26.4
Long term investments
Property, plant & equipment $10.02 $11.25 $11.92 $7.68
Goodwill & intangible assets $5.34 $6.01 $6.67 $7.34
Total noncurrent assets $15.73 $17.62 $18.95 $15.51
Total investments $8.01 $18.5
Total assets $77.88 $54.25 $41.29 $41.91
Current liabilities
Accounts payable $1.57 $2.9 $1.72 $1.96
Deferred revenue $0.02
Short long term debt $1.81 $1.21 $0.54
Total current liabilities $5.98 $8.52 $7.58 $4.46
Long term debt $65 $10.04 $10.81 $6.72
Total noncurrent liabilities $74.14 $10.04 $10.81 $6.72
Total debt $75.96 $11.25 $11.36 $6.72
Total liabilities $80.13 $18.56 $18.4 $11.18
Shareholders' equity
Retained earnings -$294.7 -$236.2 -$172.54 -$122.69
Other shareholder equity -$0 $0
Total shareholder equity -$2.25 $35.69 $22.89 $30.74
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Dec 2022
Revenue
Total revenue -$0.01
Cost of revenue $1.29
Gross Profit -$1.3
Operating activities
Research & development $7.47 $6.7 $5.83 $4.09
Selling, general & administrative $3.78 $3.53 $3.73 $3.35
Total operating expenses $11.25 $10.23 $9.56 $7.45
Operating income -$11.25 -$10.23 -$9.56 -$8.74
Income from continuing operations
EBIT -$9.88 -$9.91 -$9.56 -$8.74
Income tax expense
Interest expense $0.69 $0.24 $0.45
Net income
Net income -$10.57 -$9.91 -$9.8 -$9.2
Income (for common shares) -$10.57 -$9.91 -$9.8 -$9.2
(in millions $) 31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Revenue
Total revenue $0.7 $1.42
Cost of revenue $11.94 $1.97
Gross Profit -$11.24 -$0.55
Operating activities
Research & development $20.84 $28.64 $26.44 $24.96
Selling, general & administrative $25.97 $33.82 $22.86 $22.33
Total operating expenses $46.81 $62.46 $49.97 $47.95
Operating income -$58.06 -$63.01 -$49.97 -$47.95
Income from continuing operations
EBIT -$58.06 -$64.31 -$49.85 -$46.97
Income tax expense
Interest expense $0.45 -$0.65
Net income
Net income -$58.51 -$63.66 -$49.85 -$46.97
Income (for common shares) -$58.51 -$63.66 -$49.85 -$46.97
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Dec 2022
Net income -$10.57 -$9.91 -$9.8 -$9.2
Operating activities
Depreciation $0.3 $0.3 $0.3 $0.34
Business acquisitions & disposals
Stock-based compensation $1.8 $1.14 $0.9 $0.75
Total cash flows from operations -$10.49 -$9.2 -$6.57 -$7.96
Investing activities
Capital expenditures -$0.02 -$0.02 -$0.04 -$0.04
Investments
Total cash flows from investing -$0.02 -$0.02 -$0.04 -$0.04
Financing activities
Dividends paid
Sale and purchase of stock $0.41 $14.7 $0.48 -$0.02
Net borrowings $1.74 -$0.83 -$0.92
Total cash flows from financing $2.15 $13.87 -$0.43 -$0.02
Effect of exchange rate
Change in cash and equivalents -$8.36 $4.65 -$7.04 -$8.02
(in millions $) 31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Net income -$58.51 -$63.66 -$49.85 -$46.97
Operating activities
Depreciation $1.35 $1.15 $1.09 $1.16
Business acquisitions & disposals
Stock-based compensation $5.19 $14.6 $10.07 $11.29
Total cash flows from operations -$47.01 -$54.1 -$35.37 -$34.19
Investing activities
Capital expenditures -$0.4 -$0.44 -$0.44 -$0.61
Investments $8 $10.48 -$9.49
Total cash flows from investing -$0.4 $7.56 $10.04 -$10.1
Financing activities
Dividends paid
Sale and purchase of stock $15.38 $62.51 $30.89 $0.69
Net borrowings $64.56 $0.41
Total cash flows from financing $79.94 $62.69 $30.89 $0.08
Effect of exchange rate
Change in cash and equivalents $32.52 $16.15 $5.56 -$44.2
Fundamentals
Market cap $478.96M
Enterprise value $437.96M
Shares outstanding 54.99M
Revenue -$9.00K
EBITDA -$36.86M
EBIT -$38.10M
Net Income -$39.47M
Revenue Q/Q N/A
Revenue Y/Y -100.58%
P/E ratio -12.13
EV/Sales -48.66K
EV/EBITDA -11.88
EV/EBIT -11.50
P/S ratio -53.22K
P/B ratio 9.19
Book/Share 0.95
Cash/Share 0.92
EPS -$0.72
ROA -54.67%
ROE -158.33%
Debt/Equity -35.64
Net debt/EBITDA 0.99
Current ratio 9.50
Quick ratio 9.50